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Introduction: Adipose tissue has been postulated to contribute substantially to the serum cholesteryl
ester transfer protein (CETP) pool. However, in a recent large cohort study waist circumference was not
associated with plasma CETP. The aim of the present study was to further examine associations of ac-
curate measures of body fat and body fat distribution with serum CETP concentration.
Methods: In this cross-sectional analysis of the Netherlands Epidemiology of Obesity study, we examined
in 6606 participants (aged 45e65 years) the associations of total body fat, body mass index (BMI), waist
circumference, waist-to-hip ratio (WHR), abdominal subcutaneous (aSAT) and visceral adipose tissue
(VAT) assessed with magnetic resonance imaging (n ¼ 2547) and total and trunk fat mass assessed with
dual-energy X-ray absorptiometry (n ¼ 909) with serum CETP concentration. Regression models were
adjusted for age, ethnicity, sex, dietary intake of fat and cholesterol, physical activity, smoking and
menopausal status.
Results: Mean (SD) age was 56 (6) years and BMI 26.3 (4.4) kg/m2, 56% were women. Mean serum CETP
concentration was 2.47 mg/mL. The difference in serum CETP was 0.02 mg/mL (95%CI: 0.01, 0.05) per SD
total body fat (8.7%), and 0.02 mg/mL (0.00, 0.04) per SD BMI (4.4 kg/m2). Similar associations around the
null were observed for waist circumference, WHR, aSAT, VAT, total and trunk fat mass.
Conclusion: In this population-based study, there was no evidence for clinically relevant associations
between several measures of body fat and serum CETP concentration. This ﬁnding implies that adipose
tissue does not contribute to the CETP pool in serum.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).pose tissue; BIA, bioelectrical
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Cholesteryl ester transfer protein (CETP) facilitates the net ﬂux
of cholesteryl esters from high-density lipoproteins (HDL) towards
(very) low-density lipoproteins ((V)LDL), coupled to a net ﬂux of
triglycerides (TG) from (V)LDL to HDL [1]. As such, CETP contributes
to an atherogenic lipoprotein proﬁle (i.e. high LDL/HDL-cholesterol
(C) ratio), as has been extensively studied in both humans and in
mice transgenic for human CETP [2,3].
Because CETP contributes to an adverse lipoprotein proﬁle and
high LDL-C levels have been associated with increased cardiovas-
cular disease risk [4,5], a reduction of CETP activity in plasma hass article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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reduce cardiovascular disease [6]. This could be achieved by inhi-
bition of plasma CETP with small molecules (i.e. CETP inhibitors), of
which anacetrapib [7] and TA-8995 [8] are currently being tested in
clinical trials. Inhibition of CETP expression in tissues contributing
to the pool of plasma CETP may be an alternative approach, but the
tissues and cell types responsible for determining plasma CETP
levels are still not fully elucidated.
Adipose tissue, in particular subcutaneous adipose tissue, and
the liver are the most abundant sources of CETP mRNA expression
[1,9e11] and hence they have both been postulated to contribute
substantially to the plasma CETP pool [1,12,13]. Small studies
indeed suggested that adipose tissue contributes to the plasma
CETP concentration [12,14e18]. However, most of these studies
compared measures of body fat content with plasma CETP activity
(assessed by lipid transfer between lipoproteins) [14,16,17], instead
of plasma CETP concentration by enzyme-linked immunosorbent
assay (ELISA), and plasma CETP activity is highly dependent on the
lipoprotein context during the measurement [19]. In addition, a
wide variety of methods has been used to measure CETP activity
[19], yielding comparison of CETP activity between different studies
difﬁcult. Consequently, CETP activity does not accurately represent
plasma CETP concentration and the interpretation of previous
study results regarding the contribution of adipose tissue to the
plasma CETP pool is therefore questionable. Few studies related
plasma CETP concentration to measures of body fat. One study
(n ¼ 80) found higher CETP concentrations in obese individuals
(body mass index (BMI) 30e45 kg/m2), than in lean participants
(BMI 18.5e25 kg/m2) [15], and in another study (n ¼ 44) a positive
correlation was observed between total fat mass, measured with
bioelectrical impedance analysis (BIA), and plasma CETP concen-
tration [18].
Interestingly, in a large population-based study (654 men and
780 women, 40e70 year) we recently observed that waist
circumference was not associated with the plasma CETP concen-
tration [20], which suggested that central adipose tissue does not
contribute to CETP in plasma. However, waist circumference is a
crude measure of adipose tissue mass and does not discriminate
between the abdominal subcutaneous and visceral fat depots.
Therefore, the contribution of speciﬁc adipose tissue depots to
plasma CETP remains unresolved. The aim of the present study was
to examine the associations between measures of body fat and
serum CETP concentration in a large, population-based study, to
elucidate the contribution of adipose tissue to CETP in serum.
2. Materials and methods
2.1. Study design and study population
The Netherlands Epidemiology of Obesity (NEO) study is a
population-based prospective cohort study of men and women
aged between 45 and 65 years, with an oversampling of persons
with a BMI of 27 kg/m2 or higher. The present study is a cross-
sectional analysis of the baseline measurements. Detailed infor-
mation about the study design and data collection has been
described elsewhere [21].
NEO study participants were recruited from September 2008
until September 2012 in the greater area of Leiden, The
Netherlands, to build up a population-based cohort of 6671 par-
ticipants. Men and women out of four Dutch municipalities, aged
between 45 and 65 years with a BMI of 27 kg/m2 or higher were
eligible to participate. From one municipality (Leiderdorp, The
Netherlands) all inhabitants aged between 45 and 65 years were
invited to participate regardless of their BMI, in order to obtain a
reference distribution for BMI. Participants visited the NEO studycenter after an overnight fast of at least 10 h for extensive baseline
measurements, including blood sampling and anthropometry.
Research nurses recorded currentmedication use. Prior to the study
visit, participants completed questionnaires at home with respect
to demographic, lifestyle, and clinical information.
At the study center participants completed a screening form,
asking about anything that might create a health risk or interfere
with magnetic resonance imaging (MRI) (most notably metallic
devices or claustrophobia). A body circumference of more than
1.70 m was an additional contraindication for undergoing MRI. Of
the participants who were eligible for MRI, approximately 35%
were randomly selected to undergo direct assessment of abdominal
subcutaneous adipose tissue (aSAT) and visceral adipose tissue
(VAT). Another random subset, approximately 15% of the total
population, underwent dual-energy X-ray absorptiometry (DXA) to
measure total fat mass and trunk fat mass. In the present analysis,
we excluded study participants with missing data on serum CETP
concentration (n ¼ 65). The present study population therefore
comprises 6606 participants.
The NEO study was approved by the medical ethics committee
of the Leiden University Medical Center (LUMC) and all participants
gave written informed consent.2.2. Measures of body fat
Body weight and total body fat were determined with the Tanita
bio-impedance balance (TBF-310, Tanita International Division, UK)
without shoes andwith subtraction of 1 kg to correct for theweight
of clothing. BMI was calculated by dividing the weight in kilograms
by the height in meters squared. During physical examinationwaist
circumference was measured mid-way between the lower costal
margin and the iliac crest and hip circumference was measured at
the maximum circumference of the buttocks. Subsequently the
waist-to-hip-ratio (WHR) was calculated.
aSAT and VAT were quantiﬁed by MRI. Of the total NEO study
population 2580 participants underwent MRI of the abdomen. MRI
images were acquired during a breath-hold using a turbo spin echo
imaging protocol (1.5 T MR system, Philips Medical Systems, Best,
The Netherlands). Three transverse images with a slice thickness of
10 mm were obtained at the level of the ﬁfth lumbar vertebra.
Abdominal subcutaneous and visceral fat depots were quantiﬁed
by converting the number of pixels to square cm (MASS, Medis,
Leiden, the Netherlands). The average of the three slices was used
for analyses. In 11 participants the images were of insufﬁcient
quality for the quantiﬁcation of aSAT and VAT, and therefore 2569
participants had a successful measurement of aSAT and VAT.
DXA was performed in 915 NEO study participants. With a
whole body DXA scan (Hologic Discovery A, Tromp Medical BV,
Castricum, The Netherlands) total fat mass (kg) was measured. The
abdominal region was deﬁned as 20% from pelvis cut to neck cut,
and trunk fat mass (kg) comprised the weight of adipose tissue in
this region. 912 participants had successful measurements of total
and trunk fat mass, as three DXA scans were of insufﬁcient quality.2.3. Serum CETP concentration
During the visit to the NEO study center venous blood samples
were obtained from the antecubital vein from all participants after
a 10 h overnight fast. Aliquots of plasma and serum were stored
after centrifugation at80 C. From 11 April until 16 July 2014 CETP
concentrations in serum that had undergone one previous freeze-
ethaw cycle were measured with ELISA kits according to the
manufacturer's instructions (DAIICHI CETP ELISA, Daiichi, Tokyo,
Japan).
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Questionnaires were sent to all participants and completed at
home. The general questionnaire included questions on de-
mographic, lifestyle and clinical data. Smoking status was catego-
rized into never smoker, former smoker and current smoker.
Menopausal status was classiﬁed as premenopausal, perimeno-
pausal (menopausal during last year) or postmenopausal. Partici-
pants were classiﬁed as having pre-existing cardiovascular disease
when a medical history of myocardial infarction, angina, congestive
heart failure, stroke or peripheral vascular disease was reported via
the questionnaire. Participant were classiﬁed as having diabetes
when the disease was self-reported via the questionnaire, when
anti-diabetic medication was used, or when a fasting glucose
7.0 mmol/L was measured at baseline. Dietary intake of energy,
fat, cholesterol and alcohol was assessed with a semi-quantitative
food frequency questionnaire (FFQ) [22], and calculated from the
FFQ using the 2011 version of the Dutch food composition table
(NEVO-2011). Nutrient intake was expressed as energy percentage
(En%) of total energy intake. Physical activity during leisure time
was evaluated with the short questionnaire to assess health-
enhancing physical activity (SQUASH) [23], and expressed as
metabolic equivalents of task (MET)*hours/week, with MET indi-
cating the intensity of an activity. Fasting serum total cholesterol
and TG concentrations weremeasuredwith enzymatic colorimetric
assays (Roche Modular P800 Analyzer, Roche Diagnostics, Man-
nheim, Germany) and fasting serum HDL-C concentrations with
third generation homogenous HDL-C methods (Roche Modular
P800 Analyzer, Roche Diagnostics, Mannheim, Germany). Fasting
LDL-C concentrations were calculated using the Friedewald equa-
tion [24].
2.5. Statistical analyses
In the NEO study, individuals with a BMI of 27 kg/m2 or higher
were oversampled. To correctly represent baseline associations in
the general population [25], adjustments for the oversampling of
individuals with a BMI 27 kg/m2 were made. This was done by
weighting all participants towards the BMI distribution of partici-
pants from the Leiderdorp municipality [26], whose BMI distribu-
tion was similar to the BMI distribution of the general Dutch
population in the age range of 45e65 years [27]. In practice, this
means that participants with a lower BMI were assigned larger
weights than participants with a higher BMI in the analyses. All
results are based on weighted analyses, and therefore apply to a
population-based study without oversampling of individuals with
overweight or obesity. As a consequence, the weighted character-
istics of the population are expressed in proportions instead of
absolute numbers.
Descriptive statistics of the study population were summarized
as mean (standard deviation, SD) or proportions and stratiﬁed by
sex and total body fat. We considered total body fat assessed with
BIA a more accurate measure of body fat than BMI, and categorized
a total body fat percentage greater or equal to 25% as high body fat
in men, and greater or equal to 35% as high body fat in women
[28e30].
Weighted linear regression analyses were performed to evaluate
the associations between standardized z-scores of measures of
body fat (i.e. total body fat, BMI, weight circumference, WHR, aSAT,
VAT, total fat mass and trunk fat mass) and serum CETP concen-
tration. Differences in serum CETP concentration (beta coefﬁcients
from linear regression) were expressed per SD increase in body fat
measure. Standardization of body fat measures allowed for com-
parison of the strengths of the associations between the different
body fat determinants. Crude models (model 1) were adjusted forage, ethnicity and sex (model 2). Subsequently, dietary fat intake,
dietary cholesterol intake, physical activity, smoking status and
menopausal status were added as confounding variables (model 3).
As total body fat is strongly related to waist circumference, WHR,
VAT and trunk fat mass [31], the linear regression models of the
associations between each of these variables and serum CETP
concentration were additionally adjusted for total body fat per-
centage (model 4). Weighted mean differences and corresponding
95% conﬁdence intervals (CI) were reported. We examinedwhether
associations differed between men and women by including
product terms between sex and measures of body fat in the
regression models. As there is evidence that lipid-lowering drugs
(e.g., statins, ﬁbrates and niacin) lower the plasma CETP concen-
tration [32e37], we also examined the presence of interaction be-
tween lipid lowering drug use and measures of body fat by
including product terms of lipid lowering drug use with measures
of body fat into the models. When product terms were statistically
signiﬁcant, stratiﬁed analyses were performed.
All analyses were performed using STATA Statistical Software
(Statacorp, College Station, Texas, USA), version 12.0.
3. Results
3.1. Population characteristics
Descriptive statistics of the 6606 included participants are
presented in Table 1. Serum CETP concentrations were similar for
participants with high and lower body fat, both inmen andwomen.
Lipid lowering drugs were used by 10.7% of participants (10.4%
used a statin, 0.1% a ﬁbrate, 0.1% both a statin and a ﬁbrate, and 0.1%
a bile acid sequestrant, a cholesterol absorption inhibitor or niacin).
Of the lipid lowering drug users, 38% were women and mean (SD)
age was 59 (5) years. For men mean (SD) total body fat was 27.8
(6.1)% and for women 40.9 (5.8)%. 5572 participants did not use
lipid-lowering drugs, 58% were women and mean (SD) age was 55
(6) years. For men mean (SD) total body fat was 24.5 (5.7)% and for
women 36.6 (6.6)%.
Serum CETP concentration was higher in women (2.60 mg/mL,
95% CI 2.57, 2.63) than in men (2.31 mg/mL, 95% CI 2.28, 2.34). Fig. 1
shows that serum CETP concentrations were lower in users of lipid
lowering drugs than in non-users, both in men (1.98 mg/mL, 95% CI
1.90, 2.06 vs 2.37 mg/mL, 95% CI 2.34, 2.40) and in women (2.21 mg/
mL, 95% CI 2.11, 2.32 vs 2.63 mg/mL, 95% CI 2.60, 2.66).
3.2. Associations between measures of body fat and serum CETP
concentration
In Table 2 the crude and adjusted differences in serum CETP
concentration per SD of the body fat measures are presented. After
adjustment for all potential confounding factors total body fat,
waist circumference, WHR, aSAT and trunk fat mass were not
associated with serum CETP concentration. Per 4.4 kg/m2 increase
in BMI the difference in serum CETP was 0.02 mg/mL (95% CI 0.00,
0.04). Per 56.3 cm2 increase in VAT the difference in serum CETP
was 0.05 mg/mL (95% CI 0.10, 0.01). Per 7.0 kg increase in total
fat mass (DXA) the difference in serum CETP was0.06 mg/mL (95%
CI 0.10, 0.02). Fig. 2 shows the differences in serum CETP con-
centration per SD of the body fat measures, after adjustment for all
confounding factors.
The associations between the measures of body fat and serum
CETP concentration did not differ between men and women (p-
values of product terms of measures of body fat with sex ranged
from 0.154 to 0.988 in adjusted models). Likewise, the associations
between body fat measures and serum CETP concentration did not
differ between users and non-users of lipid lowering drugs (p-
Table 1
Demographic and clinical characteristics of the Netherlands Epidemiology of Obesity study population (aged 45e65 years) without participants with missing data on serum
CETP concentration, stratiﬁed by sex and total body fat.
Characteristics Men Women
Total body fat (%)a
<25 25 <35 35
Proportion of participants (%) 24 20 21 35
Ethnicity (% white) 94 97 93 95
Age (year) 56 (7) 56 (7) 55 (5) 56 (5)
Educational level (% highb) 55 40 55 38
Tobacco smoking (% current and former smokers) 60 72 56 60
Physical activity during leisure time (MET hours/week) 40 (37) 37 (39) 40 (26) 34 (28)
Menopausal status (% postmenopausal) e e 56 63
Mean daily dietary intake
Dietary fat intake (En% derived from total fat intake) 33.9 (6.0) 34.5 (6.5) 34.2 (4.9) 34.3 (5.3)
Dietary cholesterol intake (mg/day) 219 (93) 236 (108) 178 (68) 192 (72)
Alcohol intake (g/day) 19 (19) 22 (23) 10 (9) 11 (12)
Measures of body fat
Total body fat (%) 20.8 (3.2) 29.9 (5.1) 30.1 (3.4) 40.9 (4.0)
Body mass index (kg/m2) 24.6 (2.2) 29.5 (3.8) 22.1 (1.7) 28.2 (4.4)
Waist circumference (cm) 92 (7) 106 (11) 76 (5) 94 (11)
Waist-to-hip ratio 0.91 (0.06) 0.98 (0.06) 0.80 (0.05) 0.87 (0.06)
Abdominal subcutaneous fat (cm2) 167 (52) 264 (91) 180 (48) 316 (86)
Abdominal visceral fat (cm2) 88 (43) 150 (67) 39 (18) 87 (40)
Total fat mass (kg) 20.1 (4.1) 29.6 (8.1) 19.6 (3.2) 31.9 (7.8)
Trunk fat mass (kg) 9.9 (2.6) 16.0 (4.6) 8.2 (2.0) 15.1 (4.1)
Fasting serum concentrations
CETP (mg/mL) 2.30 (0.63) 2.32 (0.70) 2.58 (0.58) 2.61 (0.63)
Total cholesterol (mmol/L) 5.48 (1.07) 5.56 (1.21) 5.69 (0.87) 5.86 (1.01)
HDL-cholesterol (mmol/L) 1.44 (0.39) 1.24 (0.34) 1.94 (0.40) 1.64 (0.39)
LDL-cholesterol (mmol/L) 3.47 (1.00) 3.52 (1.12) 3.34 (0.81) 3.63 (0.92)
Triglycerides (mmol/L) 1.19 (0.95) 1.67 (1.15) 0.86 (0.45) 1.23 (0.71)
Comorbidity and medication
Diabetes (%) 3 13 1 6
Cardiovascular disease (%) 6 10 3 6
Lipid lowering drugs (%) 9 22 2 10
Results are based on analyses weighted towards the normal BMI distribution, with n ¼ 6606 (3134 men; 3472 women)c; magnetic resonance imaging was performed in a
random subsample with n ¼ 2547, dual-energy X-ray absorptiometry was performed in a random subsample with n ¼ 909.
BMI, body mass index; CETP, cholesteryl ester transfer protein; En%, energy percent; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic equivalents
of task.
a High body fat was deﬁned as a total body fat percentage 25% for men and 35% for women [48].
b High educational level: higher secondary education (according to Dutch educational system), higher vocational education, university, PhD.
c Missing data: n ¼ 13 for ethnicity, n ¼ 68 for educational level, n ¼ 8 for smoking status, n ¼ 3 for menopausal status, n ¼ 5 for dietary fat intake, n ¼ 4 for dietary
cholesterol intake, n ¼ 4 for alcohol intake, n ¼ 120 for physical activity, n ¼ 31 for total body fat, n ¼ 7 for waist circumference, n ¼ 7 for waist-to-hip ratio, n ¼ 20 for total
cholesterol, n ¼ 21 for HDL-cholesterol, n ¼ 22 for LDL-cholesterol, n ¼ 21 for triglycerides, n ¼ 28 for cardiovascular disease, n ¼ 40 for diabetes.
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drug use ranged from 0.053 to 0.934 in adjustedmodels), except for
total body fat. The p-value for the product term of total body fat
with lipid lowering drug usewas 0.039. Analyses stratiﬁed by use of
lipid lowering drugs showed after adjustment for all potential
confounding factors, that for users of lipid lowering drugs the dif-
ference in serum CETP was 0.02 mg/mL (95% CI -0.11, 0.07) per SD
of total body fat (8.8%), and for non-users the difference was
0.06 mg/mL (95% CI 0.03, 0.09) per SD of total body fat (8.6%).
4. Discussion
Based on the contradiction between ﬁndings of initial small
studies reporting a positive relation between body fat and plasma
CETP [12,14e18], and our recent ﬁnding that waist circumference
was not associated with plasma CETP concentration [20], we aimed
to further examine the contribution of adipose tissue to the serum
CETP concentration in a large, population-based study. In 6606
participants of the NEO study body fat and body fat distribution
were extensively characterised using anthropometric measures,
BIA, MRI and DXA. There was no evidence for clinically relevant
associations between measures of body fat and serum CETP con-
centration as assessed by ELISA. This ﬁnding implies that adipose
tissue does not contribute to the CETP pool in serum.Several previous studies showed a positive association between
body fat and plasma CETP [12,14e18], but these studies were
relatively small, and mostly measured plasma CETP activity.
Various CETP activity assays have been developed that measure
either exogenous or endogenous lipid transfer capacity of CETP.
Since endogenous CETP activity measurements are dependent on
the lipoprotein concentrations in plasma, such assays do not
necessarily reﬂect CETP concentration [19]. Furthermore, several of
these studies presented merely crude differences and correlations,
and did not account for any potential confounding factors. In the
present study total body fat, waist circumference, WHR, aSAT and
trunk fat mass were not associated with serum CETP concentration
after adjustment for potential confounding factors. Although BMI,
VAT and total fat mass (DXA) were statistically signiﬁcant associ-
ated with serum CETP, the associations were weak and in opposite
directions. For example, for an individual with a length of 1.80 m,
the association of BMI represents a 0.8% increase in mean serum
CETP concentration (2.47 mg/mL) following aweight gain of 14.3 kg.
Therefore, we consider these associations to be of no clinical
relevance.
Since we and others have shown that lipid-lowering drugs,
including statins, decrease the plasma CETP concentration [32e37],
we tested for interaction between lipid lowering drug use and
measures of body fat. Except for total body fat, there was no
Fig. 1. Mean serum CETP concentration in non-users and users of lipid lowering drugs,
stratiﬁed by sex. Results are based on analyses weighted towards the normal BMI
distribution, with n ¼ 6606; 1034 users of lipid lowering drugs, 5572 non-users. Error
bars represent 95% conﬁdence intervals.
Table 2
Difference in serum CETP concentration per standard deviation body fat measure, for th
Body fat measure Model Differen
Total body fat 1 0.11
SD: 8.7% 2 0.03
3 0.02
Body mass index 1 0.01
SD: 4.4 kg/m2 2 0.03
3 0.02
Waist circumference 1 0.05
SD: 13.4 cm 2 0.01
3 0.01
4b 0.03
Waist-to-hip ratio 1 0.09
SD: 0.08 2 0.01
3 0.01
4b 0.03
Abdominal subcutaneous adipose tissue 1 0.04
SD: 97.1 cm2 2 0.00
3 0.00
Visceral adipose tissue 1 0.10
SD: 56.3 cm2 2 0.04
3 0.04
4b 0.05
Total fat mass 1 0.01
SD: 7.0 kg 2 0.05
3 0.06
Trunk fat mass 1 0.05
SD: 4.0 kg 2 0.05
3 0.06
4b 0.07
Results are based on analyses weighted towards the normal BMI distribution, with n ¼
n ¼ 2547, dual-energy X-ray absorptiometry was performed in a random subsample wi
Model 1: crude.
Model 2: adjusted for age, ethnicity and sex.
Model 3: model 2 þ adjusted for dietary fat intake, dietary cholesterol intake, physical a
Model 4b: model 3 þ adjusted for body fat percentage.
a Beta coefﬁcients from linear regression; expressed per SD increase in body fat meas
b Additional adjustment for body fat percentage was restricted to the linear regression
visceral fat.
c Missing data: n ¼ 31 for total body fat, n ¼ 7 for waist circumference, n ¼ 7 for wa
cholesterol intake, n ¼ 120 for physical activity, n ¼ 8 for smoking status, n ¼ 3 for men
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drugs. This indicates that, although users of lipid lowering drugs
have lower serum CETP concentrations, the associations between
these body fat measures and serum CETP concentration do not
differ between users and non-users of lipid lowering drugs. The
exclusion of users of lipid lowering drugs in the model for total
body fat showed a difference of 0.06 mg/mL (95% CI 0.03, 0.09) in
serum CETP concentration per 8.6% increase in total body fat. We
consider this association to be clinically irrelevant.
The detection of statistically signiﬁcant, but clinically irrelevant
associations may be explained by the large sample size of the
present study, making it possible to detect even very small differ-
ences. Moreover, BMI and total body fat are less precisemeasures of
body fat than DXA measurements [38], which were not positively
associated with serum CETP concentration. We observed a weak
negative association between total fat mass (DXA) and serum CETP
concentration (0.06 mg/mL per 7.0 kg higher total fat mass),
arguing against the contribution of adipose tissue to CETP in serum.
It has been suggested that there are tissue speciﬁc differences in
the contribution of adipose tissue to plasma CETP [12,17], as the
expression of CETP mRNA in subcutaneous adipose tissue is higher
than in visceral adipose tissue [11]. In this large study population
there was no positive associations between either aSAT or VAT with
serum CETP concentration (n ¼ 2547), indicating that neithere total study population.
ce in serum CETP concentration (mg/mL)a 95% conﬁdence interval
0.09, 0.13
0.00, 0.06
0.01, 0.05
0.01, 0.03
0.01, 0.05
0.00, 0.04
0.07, 0.03
0.01, 0.03
0.02, 0.03
0.07, 0.02
0.12, 0.07
0.04, 0.02
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Fig. 2. Adjusted difference a in serum CETP concentration per standard deviation body fat measure, for the total study population. Results are based on analyses weighted towards
the normal BMI distribution, with n ¼ 6606; magnetic resonance imaging was performed in a random subsample with n ¼ 2547, dual-energy X-ray absorptiometry was performed
in a random subsample with n ¼ 909. Error bars represent 95% conﬁdence intervals. a Beta coefﬁcient from linear regression adjusted for age, ethnicity, sex, dietary fat intake,
dietary cholesterol intake, physical activity, smoking and menopausal status. Additional adjustment for body fat percentage was restricted to the linear regression analyses of waist
circumference, waist-to-hip ratio, trunk fat mass and abdominal visceral fat.
L.L. Blauw et al. / Atherosclerosis 246 (2016) 267e273272visceral nor subcutaneous adipose depots contributes to the plasma
CETP concentration. Recently, we observed in 93 obese individuals
that the CETP mRNA expression in the liver largely exceeds the
expression in both subcutaneous and visceral adipose tissue [20]. In
the liver CETP expression in conﬁned to hepatic macrophages
(Kupffer cells) and hepatic Kupffer cell content strongly correlates
with plasma CETP concentration [20].
It is of interest that weight loss was shown to decrease plasma
CETP concentration [17,39e41], which at ﬁrst glance may seem to
be contrary to our present ﬁndings. However, it is plausible that
effects other than a reduction in adipose tissue caused the observed
decrease in plasma CETP concentration. Since weight reduction is
accompanied by a decrease in hepatic inﬂammation [42,43], a
reduction in Kupffer cell content could be responsible for the
decrease of plasma CETP. Another mechanism that might explain a
decrease in plasma CETP after weight loss is diminished activation
of the liver X receptor a (LXRa). The natural ligands for LXRa are
oxysterols and the expression of CETP is mainly under control of
this receptor [44,45]. We speculate that a decrease in oxysterols
following weight loss might lead to diminished activation of LXRa,
and consequently lower CETP production.
The main strength of the present study is the availability of
several accurate measures of body fat and body fat distribution, in
addition to information on multiple potential confounding factors.
The observational design is however a limitation, as we cannot
exclude the presence of residual confounding by unknown, un-
measured or not accurately measured confounding factors. Besides,
the study population was predominantly white and results may
therefore not apply to other ethnical groups.
In conclusion, in this large population-based study there was no
evidence for clinically relevant associations of total body fat, body
mass index, waist circumference, waist-to-hip ratio, subcutaneous
adipose tissue (MRI), visceral adipose tissue (MRI), total fat mass
(DXA) and trunk fat mass (DXA) with serum CETP concentration.
These ﬁndings imply that adipose tissue does not contribute to the
CETP pool in serum. To fully understand the role of CETP in car-
diovascular disease, future research is needed regarding the phys-
iology and biological function of CETP, especially in light of the
termination of the recent clinical trials with the CETP inhibitors
dalcetrapib [46] and evacetrapib [47], both due to insufﬁcient
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